Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib for MRD in Philadelphia-chromosome positive acute lymphoblastic leukemia
2019-004491-19Phase 2Completed
- Sponsor
- Universitätsklinikum Frankfurt
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in acute lymphoblastic leukemia (ALL) and leukemia, sponsored by Universitätsklinikum Frankfurt. Primary endpoint: Molecular remission after one cycle of ponatinib. Started Jun 2020; status: completed.
02
Drugs
ponatinib
03
Conditions
acute lymphoblastic leukemia (ALL)leukemia
Beyond the preview
Go deeper on 2019-004491-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004491-19.